Increased CD38 surface expression in SLE T cells is more prevalent in clinically active SLE patients, while high levels of anti-CD38 autoantibodies are more frequent in quiescent SLE patients with low levels of anti-dsDNA autoantibodies19. This evidence concerns the gene CD38 and systemic lupus erythematosus.